• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

    PR NEWSWIRE

    I-Mab to Release Q3 2024 Financial Results on November 14, 2024

    PR NEWSWIRE

    I-Mab Presents Givastomig Phase 1 Data at SITC 2024

    PR NEWSWIRE

    I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

    PR NEWSWIRE

    I-Mab Presents Uliledlimab PK Data At WCLC 2024

    PR NEWSWIRE

    I-Mab To Participate In H.C. Wainwright Global Investment Conference

    PR NEWSWIRE

    I-Mab to Release 1H 2024 Financial Results on August 28, 2024

    PR NEWSWIRE

    I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

    PR NEWSWIRE

    I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

    PR NEWSWIRE

    I-Mab Ragistomig Phase 1: Encouraging Pd-L1X4-1Bb At Asco 2024

    GLOBENEWSWIRE

    I-MAB Filed 2023 Annual Report on Form 20-F

    PR NEWSWIRE

    I-Mab CEO details considerations behind China split, hints in-licensing

    ENDPTS

    I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

    PR NEWSWIRE

    Three more I-Mab execs exit after US/China operations split

    ENDPTS

    I-Mab Reports Full Year 2023 Financial Results and Business Update

    PR NEWSWIRE

    I-Mab divests China business to become US-based biotech firm

    BIOSPECTRUM ASIA

    I-Mab sheds China footprint to transform into US-based biotech

    FIERCE BIOTECH

    I-Mab Announces Participation at Jefferies and Piper Conferences in November

    PR NEWSWIRE

    Felzartamab Granted Breakthrough Therapy Designation by FDA for PMN

    PR NEWSWIRE

    I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio

    PR NEWSWIRE

    I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

    PR NEWSWIRE

    I-Mab and ABL Bio Announce Latest Updates of Antibody TJ-L14B/ABL503

    PR NEWSWIRE

    AbbVie terminates deal with I-Mab to develop cancer drug

    REUTERS

    I-Mab Announces Upcoming Participation at September Conferences

    PR NEWSWIRE

    I-Mab to seek approval of pediatric growth hormone deficiency drug in China

    ENDPTS

    I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

    PR NEWSWIRE

    I-Mab to Report Mid-Year 2023 Financial Results

    PR NEWSWIRE

    I-Mab Announce Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig

    PR NEWSWIRE

    I-Mab Announces the Appointment of Raj Kannan as CEO

    PR NEWSWIRE

    I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with NSCLC

    PR NEWSWIRE

    I-Mab Announces Poster Presentation CD73 Antibody Uliledlimab at ASCO 2023

    PR NEWSWIRE

    I-Mab Announces Outcome in Arbitration Relating to Agreements with Tracon

    PR NEWSWIRE

    I-Mab Announces First Patient Dosed in Phase 3 Study of Lemzoparlimab

    PR NEWSWIRE

    I-Mab Reports Financial Results for the Year Ended December 31, 2022

    PR NEWSWIRE

    I-Mab to Report Full Year 2022 Financial Results on March 31, 2023

    PR NEWSWIRE

    I-Mab Receives “A” Rating in Updated MSCI ESG Assessment

    PR NEWSWIRE

    I-Mab Announces Two Presentations of CD47 Antibody Lemzoparlimab at ASH 2022

    PRNEWSWIRE

    I-Mab to Present CD47 Antibody Lemzoparlimab & CD73 Antibody Uliledlimab

    PRNEWSWIRE

    I-Mab Announces Approval to Initiate PIII Study of Lemzoparlimab & Azacitidine

    PRNEWSWIRE

    I-Mab Announces Positive Phase 2 Data of Lemzoparlimab with Azacitidine

    PRNEWSWIRE

    I-Mab to Present PII Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

    PRNEWSWIRE

    I-Mab Reports Financial Results for the Six Months Ended June 30, 2022

    PRNEWSWIRE

    China and US consider possible solution for US-listed companies

    ENDPTS

    I-Mab Announces Share Purchase Plans by the Company and the Senior Management

    PRESS RELEASE

    I-Mab to Report Financial Results for the Six Months

    PRNEWSWIRE

    AbbVie calls off PI trial for I-Mab’s CD47 after Zai Lab shelves program

    ENDPTS

    I-Mab Begins Dosing in PI Trial of Claudin 18.2 and 4-1BB Bispecific Ab TJ-CD4B

    PRNEWSWIRE

    BMS vets tie up another all-stock deal

    ENDPTS

    AbbVie terminates early-stage study of I-Mab`s antibody

    ENDPTS

    I-Mab to Present PII Data of CD47 Ab Lemzoparlimab at ESMO 2022

    PRESS RELEASE

    I-Mab to Host 2022 R&D Day

    PRNEWSWIRE

    I-Mab Receives Top Rankings in Five Categories by Institutional Investor

    PRNEWSWIRE

    I-Mab Partner MorphoSys Announces License Agreements for Felzartamab and TJ210

    PRNEWSWIRE

    Genexine Completes Enrollment in PIII Trial with GX-H9/TJ101

    BIOSPACE

    I-Mab concludes subject enrolment in Phase III PGHD treatment trial

    CLINICALTRIALSARENA

    I-Mab Completes Patient Enrollment in PIII Trial of Eftansomatropin alfa

    PRNEWSWIRE

    I-Mab, Junshi`s cancer combo worked best as first-line treatment

    FIERCEBIOTECH

    I-Mab Reports Latest PII Data of its Differentiated CD73 Antibody Uliledlimab

    ASIAONE

    I-Mab to Hold Investor Call to Report Latest PII Data of Uliledlimab

    PRNEWSWIRE

    I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act

    PRNEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.